Compare JFIN & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JFIN | SPRO |
|---|---|---|
| Founded | 2011 | 2013 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.0M | 67.0M |
| IPO Year | 2018 | 2017 |
| Metric | JFIN | SPRO |
|---|---|---|
| Price | $1.31 | $1.07 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 34.9K | ★ 461.5K |
| Earning Date | 11-24-2026 | 11-12-2026 |
| Dividend Yield | ★ 61.78% | N/A |
| EPS Growth | N/A | ★ 111.81 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $66,802,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.35 | ★ N/A |
| Revenue Growth | N/A | ★ 39.24 |
| 52 Week Low | $1.13 | $1.08 |
| 52 Week High | $10.06 | $3.08 |
| Indicator | JFIN | SPRO |
|---|---|---|
| Relative Strength Index (RSI) | 40.83 | 39.23 |
| Support Level | $1.26 | N/A |
| Resistance Level | $1.62 | $1.28 |
| Average True Range (ATR) | 0.11 | 0.06 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 50.00 | 0.00 |
Jiayin Group Inc is China's technology service group. It is an enterprise engaged in technological innovation services. It is committed to using big data, cloud computing, artificial intelligence and other technologies to connect consumers and financial institutions in consumption scenarios so that every user can enjoy efficient and convenient technology services. The company has engraved technological innovation into the company's development genes since its establishment, adheres to the dual drive of digital plus technology, and focuses on building a cloud service platform and intelligent risk control system with big data drive as the core concept.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.